文献速递浆细胞疾病造血干细胞移植与细胞治疗

接受抗BCMA CAR T细胞治疗的复发/难治性多发性骨髓瘤伴髓外疾病患者的临床结局与微环境分析

Clinical outcomes and microenvironment profiling in relapsed/refractory multiple myeloma patients with extramedullary disease receiving anti-BCMA CAR T-cell-based therapy.
PubMed 文献 · Am J Hematol · 2024-08-28

这项前瞻性队列研究纳入31例经组织学确认的骨外髓外疾病(EMD)复发/难治性多发性骨髓瘤患者,于2017年5月至2023年9月接受抗BCMA联合抗CD19 CAR T细胞治疗。总体反应在髓内疾病为90.3%、EMD为64.5%(p=.031),中位随访25.3个月,中位无进展生存期和总生存期分别为5.0个月和9.7个月。

要点

  • EMD缓解率64.5%低于髓内90.3%(p=.031),且缓解欠佳、延迟、持续时间缩短。
  • 中位随访25.3个月,中位无进展生存期5.0个月,中位总生存期9.7个月。
  • 输注后6个月内进展与死亡风险增加强相关(HR=4.58;p=.029)。

核心结论

  • CAR T细胞对复发/难治性EMD有治疗活性,但长期生存获益可能有限;EMD特异性微环境可能影响治疗,需进一步努力延长EMD缓解并改善长期结局。

研究设计与样本

  • 前瞻性队列研究,纳入31例经组织学确认的骨外EMD患者,于2017年5月至2023年9月接受抗BCMA联合抗CD19 CAR T细胞治疗。

主要发现

  • 总体反应在髓内疾病为90.3%、EMD为64.5%(p=.031),EMD缓解欠佳、延迟且缓解持续时间缩短。
  • 中位随访25.3个月,中位无进展生存期为5.0个月,中位总生存期为9.7个月。
  • 里程碑分析显示输注后6个月内进展与死亡风险增加强相关(HR=4.58;p=.029)。
  • 与无EMD患者相比,EMD患者生存结局更差。
  • 22.6%患者出现EMD特有的CAR相关局部毒性,且与全身性细胞因子释放综合征的发生和严重程度相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Relapsed/refractory multiple myeloma patients with extramedullary disease (EMD) have unfavorable prognosis and lack effective therapy. Chimeric antigen receptor (CAR) T-cell activities in EMD have yet to be determined; how EMD-specific microenvironment influences the clinical outcomes of CAR T-cell therapy remains of great interest. In this prospective cohort study, patients with histologically confirmed extra-osseous EMD were enrolled and treated with combined anti-BCMA and anti-CD19 CAR T-cell therapy from May 2017 to September 2023. Thirty-one patients were included in the study. Overall response occurred in 90.3% of medullary disease and 64.5% of EMD (p = .031). Discrepancies in treatment response were noted between medullary and extramedullary diseases, with EMD exhibiting suboptimal and delayed response, as well as shortened response duration. With a median follow-up of 25.3 months, the median progression-free and overall survival were 5.0 and 9.7 months, respectively. Landmark analysis demonstrated that progression within 6 months post-infusion is strongly associated with an increased risk of death (HR = 4.58; p = .029). Compared with non-EMD patients, patients with EMD showed inferior survival outcomes. Unique CAR-associated local toxicities at EMD were seen in 22.6% patients and correlated with the occurrence and severity of systemic cytokine release syndrome. To the cutoff date, 65% treated patients experienced EMD progression, primarily in the form of BCMA+ progression. The pretherapy EMD immunosuppressive microenvironment, characterized by infiltration of exhausted CD8+ T cells, was associated with inferior clinical outcomes. CAR T cells have therapeutic activity in relapsed/refractory EMD, but the long-term survival benefits may be limited. EMD-specific microenvironment potentially impacts treatment. Further efforts are needed to extend EMD remission and improve long-term outcomes.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Qi Y, Li H, Qi K, et al. Clinical outcomes and microenvironment profiling in relapsed/refractory multiple myeloma patients with extramedullary disease receiving anti-BCMA CAR T-cell-based therapy. Am J Hematol. 2024. PMID: 39194355. doi:10.1002/ajh.27469

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。